Clinical trial NCT03363360: Comprehensive Awareness and Control in Diabetes Patients in China Jiangxi: A Cross-Sectional Survey
Official title: Comprehensive Awareness and Control in Diabetes Patients in China Jiangxi: A Cross-Sectional Survey
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: To Assess the Level of Control of Blood Glucose, Blood Pressure, and Blood Lipids Among Patients With Type 2 Diabetes in Jiangxi Province
Lead sponsor: Second Affiliated Hospital of Nanchang University
Sponsor class: OTHER
First posted: 2017-12-06
Enrollment: 2000
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: 20 to 80 - year - old diabetic patients

Brief summary: The study is a multicenter, sub-center contrast, cross-sectional survey.The primary objective of this study was to assess the Comprehensive Awareness and Control of blood glucose, blood pressure, and blood lipids among patients with type 2 diabetes in China Jiangxi. An additional objective was to investigate the impact of hospital type on clinical outcomes.

Detailed description: Background: With the continuous improvement of living standards in the past 30 years, the lifestyle and diet of Chinese people have undergone significant changes, leading to a significant increase in the prevalence of diabetes, hypertension and lipid metabolism disorders. Prevention and control work is also increasingly valued. At present, there is no research on the awareness rates and control rates of blood glucose, blood pressure and blood lipids in diabetic patients in Jiangxi Province. During the 13th Five-Year Plan period, the country has vigorously promoted the grading system of chronic non-communicable diseases, but there is a big gap between the levels of disease management in different levels of hospitals.

Methods:The province's multi-center, sub-center control, cross-sectional survey, the number of cases planned to be included in 10000 cases. Patient Access: Within 2 years from the date of the study (December 2016), eligible patients were screened out of outpatients in the participating hospitals, and patients were reviewed and informed of the informed consent.Inclusion criteria: in line with the WHO1999 diabetes diagnostic criteria; age 20-80 years; duration of 1 year or more; signed informed consent. Exclusion criteria: at the same time using other experimental drugs or in other clinical trials; gestational diabetes, other special types of diabetes; in acute infection, trauma and other stress conditions and the acute phase of the disease and other anomalies; patients with malignant tumors.

Eligibility criteria: Inclusion Criteria:

* Patients aged 20 years to 80 years who were diagnosed with diabetes according to the World Health Organization criteria, at least 1 years before screening,written informed consent

Exclusion Criteria:

* Patients if they were pregnant or Other special types of diabetes, Patients with malignant tumor,participating in any other clinical studies, In phase of acute infection, trauma, such as stress state and acute phase of disease and other anomalies

Primary outcomes:
measure: HbA1c
timeFrame: The first 30 days or seven days after the visit
measure: TC
timeFrame: The first 30 days or seven days after the visit
measure: TG
timeFrame: The first 30 days or seven days after the visit
measure: LDL-C
timeFrame: The first 30 days or seven days after the visit
measure: HDL-C
timeFrame: The first 30 days or seven days after the visit
Secondary outcomes:
measure: blood pressure
timeFrame: On the day of the visit
Other outcomes:
Locations:
city: Nanchang
country: China
facility: No.1MinDeRoad
state: Jiangxi
Study officials:
References: